Melior Will Screen AstraZeneca Compounds For Therapeutic Activity
This article was originally published in The Pink Sheet Daily
Meanwhile, the discovery firm plans to spin off a diabetes drug company with its own lead compound MLR-1023.
You may also be interested in...
Data from Pfizer on “recycled” gastric-ulcer drug will help move it into humans, Melior CEO tells “The Pink Sheet” DAILY.
J&J is third big pharma firm to sign on to use Melior’s in vivo theraTrace therapeutic indications screening platform.
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.